Compare MVBF & ORGO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MVBF | ORGO |
|---|---|---|
| Founded | 1997 | 1985 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 338.1M | 348.6M |
| IPO Year | 2004 | 2016 |
| Metric | MVBF | ORGO |
|---|---|---|
| Price | $25.77 | $2.36 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | ★ $29.50 | $8.50 |
| AVG Volume (30 Days) | 23.1K | ★ 1.7M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.62% | N/A |
| EPS Growth | 34.64 | ★ 1600.00 |
| EPS | ★ 2.06 | 0.15 |
| Revenue | $3,400,000.00 | ★ $564,169,000.00 |
| Revenue This Year | $1.70 | N/A |
| Revenue Next Year | $13.59 | $26.27 |
| P/E Ratio | ★ $12.66 | $15.50 |
| Revenue Growth | ★ 51.92 | 17.04 |
| 52 Week Low | $16.45 | $2.21 |
| 52 Week High | $29.59 | $7.08 |
| Indicator | MVBF | ORGO |
|---|---|---|
| Relative Strength Index (RSI) | 48.77 | 40.56 |
| Support Level | $25.30 | $2.26 |
| Resistance Level | $26.14 | $2.60 |
| Average True Range (ATR) | 0.54 | 0.16 |
| MACD | 0.02 | 0.03 |
| Stochastic Oscillator | 30.85 | 31.18 |
MVB Financial Corp is a financial holding company. The company provides a wide range of business activities through the Bank, commercial and retail banking services, as well as Fintech banking. It has three reportable segments: CoRe Banking, Mortgage Banking, and Financial Holding Company. The majority of its revenue is generated from the CoRe Banking segment, which includes its Fintech division, represents banking products and services offered to customers by the Bank, loans and deposits accounts. Revenue from banking activities consists of interest earned on loans and investment securities and service charges on deposit accounts.
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.